FDA approves new Rx treatment for urinary tract infections

SILVER SPRING, Md. — The U.S. Food and Drug Administration earlier this week approved Rempex Pharmaceuticals' Vabomere for adults with complicated urinary tract infections, including a type of kidney infection, pyelonephritis, caused by specific bacteria.



Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.



“The FDA is committed to making new safe and effective antibacterial drugs available,” stated Edward Cox, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research. “This approval provides an additional treatment option for patients with cUTI, a type of serious bacterial infection.”